Aim: The potential of uterine artery (UA) Doppler pulsatility index (PI) and maternal serum placental growth factor (PlGF) level to predict perinatal outcome was explored in pregnancies complicated by intrauterine fetal growth restriction (IUGR) or preeclampsia (PE). Methods: This longitudinal, prospective, and case-controlled study was conducted over a period of 24 months. At-risk pregnancies involving small-for-gestational-age (SGA) fetuses, IUGR, gestational hypertension (GH), or PE were investigated, analyzing UA Doppler PI findings and maternal PlGF levels determined at the time of diagnosis (third trimester). Results: UA Doppler PI and maternal serum PlGF values differed significantly in pregnancies complicated by IUGR and/or PE (vs. SGA or GH, p < 0.01). In the context of IUGR or PE, both parameters also differed significantly by perinatal outcome (adverse vs. normal, p < 0.01), although no predictive advantage over UA Doppler PI alone was conferred by adding a PlGF assay. Conclusion: UA Doppler PI and maternal serum PlGF determinations in the third trimester help identify pregnancies at the highest risk of adverse perinatal outcomes due to IUGR and/or PE. Although joint testing confers no predictive benefit over UA Doppler PI alone, the two diagnostics are interchangeable for this purpose.

1.
Jauniaux E, Jurkovic D, Campbell S: In vivo investigations of the anatomy and the physiology of early human placental circulations. Ultrasound Obstet Gynecol 1991;1:435-445.
2.
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH: One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000;96:559-564.
3.
Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH: Multicentric screening for preeclampsia and fetal growth restriction by transvaginal uterine Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441-449.
4.
Papageorghiou AT, Yu C, Nicolaides K: The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004;18:383-396.
5.
Chien PF, Arnott N, Gordon A, Owen P, Khan KS: How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000;107:196-208.
6.
Vergani P, Roncaglia N, Andreotti C, Arreghini A, Teruzzi M, Pezzullo JC, Ghidini A: Prognostic value of uterine artery Doppler velocimetry in growth-restricted fetuses delivered near term. Am J Obstet Gynecol 2002;187:932-936.
7.
Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Gómez-Montes E, Denk B, Galindo A: Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol 2013;41:530-537.
8.
Maroni E, Youssef A, Arcangeli T, Nanni M, De Musso F, Contro E, Kuleva M, Bellussi F, Pilu G, Rizzo N, Ghi T: Increased uterine artery pulsatility index at 34 weeks and outcome of pregnancy. Ultrasound Obstet Gynecol 2011;38:395-399.
9.
Ghi T, Contro E, Youssef A, Giorgetta F, Farina A, Pilu G, Pelusi G: Persistence of increased uterine artery resistance in the third trimester and pregnancy outcome. Ultrasound Obstet Gynecol 2010;36:577-581.
10.
Dane B, Batmaz G, Ozkal F, Bakar Z, Dane C: Effect of parity on first-trimester uterine artery Doppler indices and their predictive value for pregnancy complications. Gynecol Obstet Invest 2014;77:24-28.
11.
Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK: Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-1274.
12.
Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ: Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98:600-607.
13.
Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA: Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-182.
14.
Vandemberghe G, Mensink I, Twisk JW, Blankenstein MA, Heijboer AC, van Vugt JM: First trimester screening for intrauterine growth restriction and early-onset preeclampsia. Prenat Diagn 2011;31:955-961.
15.
Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg CS, Spencer K: First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat Diagn 2010;30:656-670.
16.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008;28:1110-1115.
17.
Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, Goffinet F, Tsarsaris V: Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012;7:e50208.
18.
Vatten LJ, Asvold BO, Eskild A: Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. Acta Obstet Gynecol Scand 2012;91:1388-1394.
19.
Weed S, Bastek JA, Anton L, Elovitz MA, Parry S, Srinivas SK: Examining the correlation between placental and serum placenta growth factor in preeclampsia. Am J Obstet Gynecol 2012;207:140.e1-6.
20.
Chui A, Murthi P, Bennecke SP, Ignjatovic V, Monagle PT, Said JM: The expression of placental proteoglycans in pre-eclampsia. Gynecol Obstet Invest 2013;73:277-284.
21.
Figueras F, Meler E, Iraola A, Eixarch E, Coll O, Figueras J, Francis A, Gratacos E, Gardosi J: Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136:20-24.
22.
Turan OM, Turan S, Gungor S, Berg C, Moyano D, Gembruch U, Nicolaides KH, Harman CR, Baschat AA: Progression of Doppler abnormalities in intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;32:160-167.
23.
Alfirevic Z, Stampalija T, Gyte GML: Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2013;11:CD007529.
24.
Helewa M, Burrows R, Smith J, Williams K, Brains P, Rabkin SW: Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997;157:715-725.
25.
Duley L: Pre-eclampsia and hypertension. Clin Evid 2002;7:1296-1309.
26.
Kean L: Managing hypertension in pregnancy. Curr Obstet Gynaecol 2002;12:104-110.
27.
Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
28.
Robinson HP, Fleming JE: A critical evaluation of sonar ‘crown-rump length' measurements. BJOG 1975;82:702-710.
29.
Arduini G, Rizzo G: Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1,556 healthy foetuses. J Perinat Med 1990;18:165-172.
30.
Lobmaier SM, Figueras F, Mercade I, Crovetto F, Peguero A, Parra-Saavedra M, Ortiz JU, Crispi F, Gratacós E: Levels of maternal serum angiogenic factors in third-trimester normal pregnancies: reference ranges, influence of maternal and pregnancy factors and fetoplacental Doppler indices. Fetal Diagn Ther 2014;36:38-43.
31.
Llurba E, Turan O, Kasdaglis T, Harman CR, Baschat AA: Emergence of late-onset placental dysfunction: relationship to the change in uterine artery blood flow resistance between the first and third trimesters. Am J Perinatol 2013;30:505-512.
32.
Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L, Kublickiene K: Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol 2008;294:H1381-H1387.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.